Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-154 in Moderate to Severe Rheumatoid Arthritis
NCT04888585Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jun 2021
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 21
01
Overview
A Phase 2 trial of ABBV-154 in rheumatoid arthritis (RA), sponsored by AbbVie Inc.. Started Jun 2021; status: terminated.
02
Drugs
ABBV-154
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04888585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04888585.